In September 2021, Changzhou Tongtai Biopharmaceutical Technology Co., Ltd. participated in the research, development and application of inactivated vaccine of porcine pseudorabies virus variant strain, completed the preliminary clinical experiment and the summary of registration application data, and the main applicant, Institute of immune engineering, Jiangsu Academy of Agricultural Sciences, jointly submitted the application for registration of new veterinary drugs.

In the future, the inactivated vaccine of porcine pseudorabies virus variant strain will be approved for listing, which can further enrich the types of Tongtai biological pig vaccine series products, improve the market competitiveness of pig vaccine products, combine with the existing porcine circovirus inactivated vaccine, effectively help biological breeding enterprises solve major pig disease prevention and control problems and improve breeding benefits.